CY1109956T1 - Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη - Google Patents

Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη

Info

Publication number
CY1109956T1
CY1109956T1 CY20091100181T CY091100181T CY1109956T1 CY 1109956 T1 CY1109956 T1 CY 1109956T1 CY 20091100181 T CY20091100181 T CY 20091100181T CY 091100181 T CY091100181 T CY 091100181T CY 1109956 T1 CY1109956 T1 CY 1109956T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
donepezil
solid pharmaceutical
hydrochlorine
composition included
Prior art date
Application number
CY20091100181T
Other languages
English (en)
Inventor
Miha Vrbinc
Berta Kotar-Jordan
Rok Zupet
Matej Smrkolj
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109956(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Publication of CY1109956T1 publication Critical patent/CY1109956T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)

Abstract

Η εφεύρεση αφορά μια στερεή φαρμακευτική σύνθεση περιλαμβάνουσα ένυδρο υδροχλωρική ντονεπεζίλη και μέθοδο για την παρασκευή αυτής. Συγκεκριμένα αφορά μια σύνθεση και μια μέθοδο, όπου η υδροχλωρική ντονεπεζίλη διατηρεί την πολυμορφική μορφή αυτής και συνεπώς είναι πολύ σταθερή έναντι μετατροπής σε άλλες πολυμορφικές μορφές.
CY20091100181T 2004-10-19 2009-02-18 Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη CY1109956T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19
EP05795965A EP1811957B1 (en) 2004-10-19 2005-10-19 Solid pharmaceutical composition comprising donepezil hydrochloride

Publications (1)

Publication Number Publication Date
CY1109956T1 true CY1109956T1 (el) 2014-09-10

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100181T CY1109956T1 (el) 2004-10-19 2009-02-18 Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη

Country Status (19)

Country Link
US (3) US20090130205A9 (el)
EP (3) EP2283811A1 (el)
JP (1) JP2008517022A (el)
AT (1) ATE415148T1 (el)
CA (1) CA2584547C (el)
CY (1) CY1109956T1 (el)
DE (1) DE602005011326D1 (el)
DK (1) DK1811957T3 (el)
EA (1) EA012220B1 (el)
ES (1) ES2317313T3 (el)
HR (1) HRP20090104T3 (el)
NO (1) NO20072494L (el)
PL (1) PL1811957T3 (el)
PT (1) PT1811957E (el)
RS (1) RS51271B (el)
SI (1) SI1811957T1 (el)
UA (1) UA83152C2 (el)
WO (1) WO2006045512A1 (el)
ZA (1) ZA200704023B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
EP2037918A2 (en) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
WO2008092011A2 (en) * 2007-01-24 2008-07-31 Cook Incorporated Biofilm-inhibiting medical products
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) * 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
AU2011334679B2 (en) * 2010-11-30 2016-12-15 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
US20150216849A1 (en) 2014-02-04 2015-08-06 Forest Laboratories Holdings Ltd. Donepezil compositions and methods of treating alzheimers disease
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
SK285312B6 (sk) 1996-06-07 2006-10-05 Eisai Co., Ltd. Polymorf (III) donepezil hydrochloridu, spôsob jeho výroby a terapeutický prostriedok s jeho obsahom
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
CA2279846C (en) * 1997-02-07 2008-06-03 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
CN1195862C (zh) * 1998-02-19 2005-04-06 札幌啤酒株式会社 分离和纯化的包括在蛇麻腺中特异性表达的基因的核酸
WO2000059544A1 (fr) 1999-03-31 2000-10-12 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4107842B2 (ja) * 2000-03-01 2008-06-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 ポリビニルアルコールを配合した速崩壊性錠剤
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (el) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
AU2003280324A1 (en) * 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
US20120283291A1 (en) 2012-11-08
CA2584547A1 (en) 2006-05-04
EA012220B1 (ru) 2009-08-28
NO20072494L (no) 2007-07-02
WO2006045512A1 (en) 2006-05-04
RS51271B (sr) 2010-12-31
ES2317313T3 (es) 2009-04-16
EP2039349A1 (en) 2009-03-25
EP1811957A1 (en) 2007-08-01
CA2584547C (en) 2014-07-08
US20080063705A1 (en) 2008-03-13
SI1811957T1 (sl) 2009-04-30
PT1811957E (pt) 2009-01-27
HRP20090104T3 (en) 2009-03-31
EA200700673A1 (ru) 2007-10-26
US20090130205A9 (en) 2009-05-21
DK1811957T3 (da) 2009-03-30
EP1811957B1 (en) 2008-11-26
ATE415148T1 (de) 2008-12-15
UA83152C2 (ru) 2008-06-10
JP2008517022A (ja) 2008-05-22
PL1811957T3 (pl) 2009-05-29
ZA200704023B (en) 2008-04-30
EP2283811A1 (en) 2011-02-16
US20100317694A1 (en) 2010-12-16
DE602005011326D1 (de) 2009-01-08

Similar Documents

Publication Publication Date Title
CY1109956T1 (el) Στερεα φαρμακευτικη συνθεση περιλαμβανουσα υδροχλωρικη ντονεπεζιλη
FR22C1008I2 (fr) Composition immunogène
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
IS8136A (is) N-pýrrólidín-3-ýl-amíð afleiður sem serótónín og noradrenalín endurupptöku hindrar
DK3090748T3 (da) Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs
DK2442107T3 (da) Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK1670458T3 (da) 1-Amino-2-oxy-substituerede tetrahydronaphthalenderivater, fremgangsmåder til fremstilling deraf og deres anvendelse som antiphlogistika
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
IS7980A (is) Díarýlmetýlídenpíperidínafleiður, framleiðsla þeirra og notkun
DK1587478T3 (da) Farmaceutisk sammensætning
BRPI0614413A2 (pt) composto, e, composição farmacêutica
DK1611115T3 (da) Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf
DK1600207T3 (da) Emulgator, fremgangsmåde til fremstilling deraf og emulgeret sammensætning der anvender emulgatoren
NO20053598L (no) Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
DK1816121T3 (da) 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter
DK1778265T3 (da) Guanylhydrazoneforbindelser, sammensætninger, fremgangsmåder og anvendelse
DK1906921T3 (da) Klar farmaceutisk, vandig mikroemulsion omfattende propofol og fremgangsmåde til fremstilling
IS8182A (is) Díarýlmetýlídenpíperídínafleiður, blöndur og notkun þeirra
ITRM20050512A1 (it) Derivati 6-pirimidinici e pirimidinonici, e loro uso.
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante